Search Within

Genitourinary Oncology Service

  1. "2012"
Formats
  1. Meeting Abstract (100)
  2. Journal Article (91)
  3. Book Section (1)
Groups
  1. Department of Medicine (192)
  2. Solid Tumor Oncology Division (192)
  3. GSK Faculty (71)
  4. Surgery (42)
  5. Human Oncology and Pathogenesis Program (40)
  6. Department of Pathology and Laboratory Medicine (33)

More Groups

People
  1. Robert Motzer (57)
  2. Howard Scher (53)
  3. David Solit (31)
  4. Michael Morris (24)
  5. Dean Bajorin (16)
  6. Darren Feldman (14)

More People

Years
  1. 2012 (192)
Publications
  1. Journal of Clinical Oncology (54)
  2. Annals of Oncology (22)
  3. BJU International (15)
  4. Cancer Research (11)
  5. Cancer (6)
  6. International Journal of Radiation Oncology, Biology, Physics (5)

More Publications

Publishers
  1. American Society of Clinical Oncology (54)
  2. Oxford University Press (23)
  3. Wiley Blackwell (22)
  4. American Association for Cancer Research (18)
  5. Elsevier Inc. (15)
  6. Elsevier Science, Inc. (15)

More Publishers

Results (192)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The analytic validation of prostate-specific mRNA detection in whole blood by RT-PCR as a prognostic biomarker for patients with castration- resistant prostate cancer (CRPC)
    Meeting Abstract

    Danila, D. C.; Anand, A.; Heller, G.; Wan, M.; Zehnder, M.; Khanin, R.; Schultz, N.; Fleisher, M.; Lilja, H.; Scher, H. I.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • External validation of a sunitinib prognostic nomogram in patients (pts) with metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Yu, C.; Kattan, M. W.; Hutson, T. E.; Hudes, G. R.; Yuan, J.; Valota, O.; Motzer, R. J.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Genetic determinants of long-term response to rapalog therapy in advanced renal cell carcinoma (RCC)
    Meeting Abstract

    Voss, M. H.; Hakimi, A. A.; Scott, S. N.; Takeda, S.; Liu, H.; Chen, Y.; Motzer, R. J.; Berger, M. F.; Hsieh, J.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • A phase II study of temsirolimus/sorafenib in patients with radioactive iodine (RAI)-refractory thyroid carcinoma
    Meeting Abstract

    Sherman, E. J.; Ho, A. L.; Fury, M. G.; Baxi, S. S.; Haque, S.; Korte, S. H.; Smith-Marrone, S.; Xiao, H.; Ghossein, R. A.; Fagin, J. A.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Targeting castration resistant prostate cancer (CRPC) with autologous PSMA-directed CAR plus T cells
    Meeting Abstract

    Slovin, S. F.; Wang, X.; Borquez-Ojeda, O.; Stefanski, J.; Olszewska, M.; Taylor, C.; Bartido, S.; Scher, H. I.; Sadelain, M.; Riviere, I.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • The impact of prior therapy with ketoconazole (keto) on clinical outcomes after subsequent docetaxel treatment in metastatic castration-resistant prostate cancer (mCRPC) patients: Results from a randomized phase III trial (CALGB 90401)
    Meeting Abstract

    Small, E. J.; Halabi, S.; Carducci, M. A.; Ryan, C. J.; George, D. J.; Mahoney, J. F.; Stadler, W. M.; Morris, M. J.; Kantoff, P.; Monk, J. P.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Cabozantinib (XL184) in chemotherapy-pretreated metastatic castration resistant prostate cancer (mCRPC): Results from a phase II nonrandomized expansion cohort (NRE)
    Meeting Abstract

    Smith, M. R.; Sweeney, C.; Rathkopf, D. E.; Scher, H. I.; Logothetis, C.; George, D. J.; Higano, C. S.; Yu, E. Y.; Harzstark, A. L.; Small, E. J.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • A phase II study of the androgen signaling inhibitor ARN-509 in patients with castration-resistant prostate cancer (CRPC)
    Meeting Abstract

    Rathkopf, D. E.; Shore, N.; Antonarakis, E. S.; Berry, W. R.; Alumkal, J. J.; Tutrone, R.; Saleh, M. N.; Redfern, C. H.; Hauke, R. J.; Liu, G.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • A phase I study of the androgen signaling inhibitor ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Rathkopf, D. E.; Morris, M. J.; Danila, D. C.; Slovin, S. F.; Steinbrecher, J. E.; Arauz, G.; Curley, T.; Rix, P. J.; Maneval, E. C.; Chen, I.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • A validated whole-blood RNA transcript-based prognostic model that predicts survival in men with castration-resistant prostate cancer
    Meeting Abstract

    Oh, W. K.; Kantoff, P.; Scher, H. I.; Magidson, J.; Wassmann, K.; Lee, G. S. M.; Katz, L. M.; Subudhi, S. K.; Anand, A.; Fleisher, M.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save